Secukinumab is an immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders. Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis.
- Mechanism
- Curator reviewed · 15 references
Interleukin-17 (IL-17) is a family of proinflammatory cytokines that mediate normal inflammatory and immune responses. The production of IL-17 is mostly promoted by T cells, such as T-helper-17 (Th17) cells, but can also be caused by mast cells and neutrophils. IL-17 binds to IL-17 receptors, which are expressed on various cell types, including keratinocytes. IL-17 signalling pathway promotes angiogenesis and the release of proinflammatory cytokines, chemokines, and mediators of tissue damage.
IL-17A is a member of IL-17 with the most prominent role in host defence and autoimmunity. IL-17A is often upregulated in several autoimmune disorders, such as psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis, making it an important therapeutic target. IL-17A is also more potent than IL-17F, another member of IL-17, with a much greater affinity to the IL-17 receptor. Secukinumab selectively binds to and inhibits IL-17A, preventing its interaction with the IL-17 receptor and activation of the IL-17 receptor signalling pathway associated with inflammatory processes.
- Primary indication
- Secukinumab is indicated the treatment of moderate to severe plaque psoriasis in patients six years and older who are candidates for systemic therapy or phototherapy.Curator reviewed · 15 structured indications
- Formula / weight
- C6584H10134N1754O2042S44 · 151000.0 Da (approximate)
- First approval
- Canada, 2015 · United States, 2015 · European Union, 2021
- Code names
- AIN-457 · AIN457A · CMAB015
- Brand names
Resolves to
What you can answer from here — as of April 07, 2026
Which drugs share a target with Secukinumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account